G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Despite substantial health benefits, two GLP-1 receptor agonists weren't cost-effective at their current prices, according to ...

Results presented here showed patients who had significant weight loss prior to total hip arthroplasty with use of a GLP-1 receptor agonist experienced a decreased risk for complications but an ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...

It’s hard to turn on the TV these days without seeing ads for drugs like Ozempic, Wegovy, Zepbound or Mounjaro. These ...

The new craze of using lower-than-recommended dosages of weight loss drugs to slim down might sound tempting, says Charlotte ...